QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: BCTXF) Initiates Patient Dosing in Combination Study of Bria-IMT
BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, this morning announced that it has initiated patient dosing in a phase I/IIa study of its lead clinical candidate, Bria-IMT, in combination with pembrolizumab [KEYTRUDA; manufactured by Merck & Co., Inc. (NYSE: MRK)] or ipilimumab [YERVOY; manufactured by Bristol-Myers Squibb Company (NYSE: BMY)]. “We believe that combination of Bria-IMT with immune checkpoint inhibitors should create even more potent anti-cancer immune responses, leading to our strategy of combination studies of Bria-IMT with KEYTRUDA or YERVOY,” Bill Williams, president and CEO of BriaCell, stated…